Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated efficacy in improving cardiorenal outcomes in patients with type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), and chronic heart failure with reduced ejection fraction (HFrEF). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.